637a6a07-fc4c-47ed-a442-a2e8368c59c6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.700
- MYC_TARGETS_V1+0.600
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- MTORC1_SIGNALING+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- HEDGEHOG_SIGNALING+0.200
- NOTCH_SIGNALING+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- SPERMATOGENESIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.400
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- APOPTOSIS-0.300
- BILE_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518345 | — | E | 0.894 |
| 2 | C3L-03965 | — | cohortSQ2 | 0.890 |
| 3 | 20120209.TNBC | — | E | 0.886 |
| 4 | TCGA-CQ-A4CI-01A-11R-A266-07 | — | — | 0.884 |
| 5 | TCGA-L3-A524-01A-11R-A262-07 | — | cohortSQ2 | 0.877 |
| 6 | SRR12696755 | — | — | 0.876 |
| 7 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.876 |
| 8 | MDT-AP-1377 | Med | Medulloblastoma | 0.876 |
| 9 | C3N-04155 | — | cohortSQ2 | 0.875 |
| 10 | SRR5088864 | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.700 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |